PTX
Click for more information
1.20% 4.2¢ prescient therapeutics limited

Ann: Encouraging data from PTX-200 ovarian cancer trial, page-171

  1. psych101
    1,656 Posts.
    lightbulb Created with Sketch. 198
    clock Created with Sketch.
    16/03/20
    08:25
    Post #: 43508134
    Interesting to see how the ptx200’s progression-free survival data is holding up on the phase 1b Ovarian readout;

    AstraZeneca and Merck & Co. have just had a set back:
    https://www.biopharmadive.com/news/astrazeneca-merck-lynparza-cediranib-ovarian-cancer/574019/
    "Measured by progression-free survival, or the length of time patients live without their tumors getting larger or spreading, the Lynparza-cediranib combination did no better than platinum-based chemotherapy."
    PTX Price at posting: 3.2¢ Sentiment: Hold Disclosure: Held
    Likes Created with Sketch. 8  Upvote
    lightbulb Created with Sketch. 3  Great analysis
    Stroke 3 Created with Sketch. Comments Created with Sketch. Reply

  2. Top Stories

 

Featured News

ALK Alkane Resources hit 57.2Kozpa gold production through FY24 – and eyeing 70Ktpa in FY26
right-arrow Created with Sketch.
A1M Swagman shoot proves plentiful for AIC, with Cu beyond 3% close to Eloise
right-arrow Created with Sketch.
AHK Ark Mines defines significant exploration target at Sandy Mitchell rare earths project
right-arrow Created with Sketch.
ARU Cashed up Arafura locks in $171M German export agency deal; locks in NdPr offtake for wind turbines
right-arrow Created with Sketch.
NEWS Finding properties tenants will want to rent
right-arrow Created with Sketch.
watchlist Created with Sketch. Add PTX (ASX) to my watchlist
(20min delay)
Last
4.2¢ 		Change
0.001(1.20%) 		Mkt cap ! $33.42M
Open High Low Value Volume
4.2¢ 4.2¢ 4.2¢ $6.887K 163.9K

Buyers (Bids)

No. Vol. Price($)
1 366 4.1¢
 

Sellers (Offers)

Price($) Vol. No.
4.2¢ 164340 2
View Market Depth
Last trade - 10.08am 05/07/2024 (20 minute delay) ?
PTX (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.